As­traZeneca stops lung can­cer tri­al ear­ly, af­ter star drug Tagris­so in­duces 'over­whelm­ing' ef­fi­ca­cy

A piv­otal lung can­cer tri­al test­ing Tagris­so, As­traZeneca’s best­selling on­col­o­gy ther­a­py, has been halt­ed due to “over­whelm­ing” ef­fi­ca­cy.

The 682 pa­tient-tri­al, ADAU­RA, was eval­u­at­ing the drug against a place­bo in non-small cell lung can­cer pa­tients with EGFR mu­ta­tions who had un­der­gone tu­mor re­sec­tion and op­tion­al, stan­dard post­op­er­a­tive ad­ju­vant chemother­a­py. In the Tagris­so arm, pa­tients were to be treat­ed with the 80 mg drug once-dai­ly for three years, or un­til the can­cer re­turned — and the da­ta read­out was sched­uled for 2022.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

Cambridge, MA, USA